A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Launched by NOVARTIS PHARMACEUTICALS · May 13, 2009
Trial Information
Current as of June 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HbA1c from 7.0-10.0%, Stable Metformin dose
- Exclusion Criteria:
- • CHF Class III-IV, Liver disease
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sherbrooke, Quebec, Canada
Montreal, Quebec, Canada
Denver, Colorado, United States
Concord, California, United States
Picayune, Mississippi, United States
Winnipeg, Manitoba, Canada
Tustin, California, United States
Mesa, Arizona, United States
Mesa, Arizona, United States
Little Rock, Arkansas, United States
Buena Park, California, United States
Pasadena, California, United States
Riverside, California, United States
San Diego, California, United States
San Diego, California, United States
Walnut Creek, California, United States
Northglenn, Colorado, United States
Miami, Florida, United States
West Palm Beach, Florida, United States
Roswell, Georgia, United States
Berwyn, Illinois, United States
Overland Park, Kansas, United States
Topeka, Kansas, United States
Bowling Green, Kentucky, United States
Madisonville, Kentucky, United States
Elkridge, Maryland, United States
Towson, Maryland, United States
Worcester, Massachusetts, United States
Bridgman, Michigan, United States
Clarkston, Michigan, United States
Kalamazoo, Michigan, United States
Springfield, Missouri, United States
Springfield, Missouri, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Brick, New Jersey, United States
Toms River, New Jersey, United States
Endwell, New York, United States
Staten Island, New York, United States
Carlisle, Ohio, United States
Greer, South Carolina, United States
Memphis, Tennessee, United States
Dallas, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Ettrick, Virginia, United States
Richmond, Virginia, United States
Bellevue, Washington, United States
Monroe, Washington, United States
Winnipeg, Manitoba, Canada
Mississauga, Ontario, Canada
Sherbrooke, Ontario, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Bergamo, , Italy
Chieti, , Italy
Milano, , Italy
Milano, , Italy
Olbia, , Italy
Pisa, , Italy
Roma, , Italy
Olawa, , Poland
Carolina, , Puerto Rico
Ponce, , Puerto Rico
San Juan, , Puerto Rico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials